Najat Khan - 05 Nov 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief R&D Commercial Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
05 Nov 2025
Net transactions value
$0
Form type
4
Filing time
06 Nov 2025, 16:23:53 UTC
Previous filing
19 Aug 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat Chief R&D Commercial Officer, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 05 Nov 2025 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +84,925 +13% $0.000000 753,122 05 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +169,851 $0.000000 169,851 05 Nov 2025 Class A Common Stock 169,851 $4.96 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on February 15, 2026, and every three months thereafter.
F2 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.